![]() ![]() ![]() Rajiv has a proven track of record of managing companies through multiple stages of growth – both organically and inorganically – and through complex turnarounds that included organizational restructuring and capital structure transformation. “He is a seasoned executive with significant experience in larger, multinational healthcare companies. “We are excited to have Rajiv join the Company to lead Venus Concept through its next stage of growth and development,” said Scott Barry, Chairman and Director of Venus Concept. De Silva has a BSE, Honors from Princeton University, an MS from Stanford University, and an MBA with Distinction from the Wharton School at the University of Pennsylvania. De Silva started his career in healthcare at McKinsey & Company in 1995, where he rose to Partner. From 2003 to 2008, he held multiple leadership positions within Novartis AG, including President, Novartis Pharma Canada. (now Bausch Health) from 2010 to 2013, and as COO of Valeant’s Specialty Pharmaceuticals business, which included its flagship dermatology and aesthetics unit, from 2009 to 2013. De Silva served as President of Valeant Pharmaceuticals International, Inc. From 2013 to 2016, he served as President, CEO and Director of Endo International Plc, a publicly traded multinational specialty pharmaceutical company. De Silva currently serves as the Chairman of Covis Pharma, a privately-held, multinational specialty pharmaceutical company, and is a co-founder of Asiri Skincare, a privately-held company focused on topical consumer therapeutic skincare products. This separation was not the result of any specific disagreement about strategy with management or the Board, inappropriate action, violation of company policy or any accounting irregularity. The Company also announced the separation of Domenic Serafino as Chief Executive Officer and Director, effective October 2, 2022. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that Rajiv De Silva has been appointed as the Company’s Chief Executive Officer and a member of the Board of Directors (the “Board”), effective October 2, 2022. 03, 2022 (GLOBE NEWSWIRE) - Venus Concept Inc. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.TORONTO, Oct. Shares of AVXL have plunged 42.9% year to date.Įarnings of Anavex beat estimates in two of the last four quarters and missed the mark on the other two occasions, the average surprise being 0.48%.įrom thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. ![]() Shares of ARDS have plunged 51.5% in the year-to-date period.Įarnings of Aridis missed estimates in two of the trailing four quarters and beat the same on the remaining two occasions, the average negative surprise being 75.16%.Īnavex Life Sciences’ loss per share estimates for 2022 have narrowed from 85 cents to 60 cents in the past 30 days. The same for 2023 has narrowed from 75 cents to 60 cents in the same time frame. ![]() Aridis Pharmaceuticals’ loss per share estimates for 2022 have narrowed from $1.78 to 34 cents in the past 30 days. ![]()
0 Comments
Leave a Reply. |